INCLUSION CRITERIA:

• acute asthma
• age 18.0 to 54.9 years
• English and/or Spanish speaking
• decision by ED attending to discharge patient to home on short course of systemic corticosteroids
• (intervention group only) Willingness to use Airsupra as their rescue inhaler for next 3 months
• demonstration of acceptable MDI administration technique
• provision of informed consent prior to any study-specific procedures

EXCLUSION CRITERIA:

• involvement in the planning and/or conduct of the study
• previous enrolment in the present study
• prior diagnosis of COPD, chronic bronchitis, or emphysema
• use of systemic corticosteroids in the past 2 weeks
• participation in another clinical study with an investigational product during the past 4 weeks or the 3 months after enrollment in the current study
• concurrent pneumonia
• clinically significant cardiovascular disease or clinically significant cancer
• patients with known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any of the excipients of the product
• (for women only, by self-report):
• currently pregnant
• currently breastfeeding,
• (among sexually active women of child-bearing age only) not using adequate contraception over the last 3 months, or no plan to use adequate contraception over the next 3 months
• lack of a working cell phone and working email address
• expected lack of availability for text and/or telephone follow-up at approximately 3, 6, and 12 weeks after the ED visit
• inability to provide an alternate contact with a working cell phone and working email address.